Seoulin Bioscience Co.Ltd
Seoulin Bioscience Co.,Ltd., a bio healthcare company, provides solutions in life sciences and healthcare primarily in South Korea. The company offers solutions for bio research and production; ecoTree, a SLB-120 instrument which produces slightly acidic electrolyzed water for used in food industry, living, and laboratory; plasma-based medical esthetics; miQ for the diagnosis of dementia; and fun… Read more
Seoulin Bioscience Co.Ltd (038070) - Net Assets
Latest net assets as of September 2025: ₩86.36 Billion KRW
Based on the latest financial reports, Seoulin Bioscience Co.Ltd (038070) has net assets worth ₩86.36 Billion KRW as of September 2025.
Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (₩113.52 Billion) and total liabilities (₩27.16 Billion). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | ₩86.36 Billion |
| % of Total Assets | 76.08% |
| Annual Growth Rate | 6.59% |
| 5-Year Change | 40.01% |
| 10-Year Change | 85.19% |
| Growth Volatility | 6.92 |
Seoulin Bioscience Co.Ltd - Net Assets Trend (2013–2024)
This chart illustrates how Seoulin Bioscience Co.Ltd's net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.
Annual Net Assets for Seoulin Bioscience Co.Ltd (2013–2024)
The table below shows the annual net assets of Seoulin Bioscience Co.Ltd from 2013 to 2024.
| Year | Net Assets | Change |
|---|---|---|
| 2024-12-31 | ₩83.89 Billion | +1.00% |
| 2023-12-31 | ₩83.06 Billion | -0.86% |
| 2022-12-31 | ₩83.79 Billion | +11.92% |
| 2021-12-31 | ₩74.86 Billion | +24.93% |
| 2020-12-31 | ₩59.92 Billion | +0.35% |
| 2019-12-31 | ₩59.71 Billion | +11.15% |
| 2018-12-31 | ₩53.72 Billion | +4.32% |
| 2017-12-31 | ₩51.49 Billion | +5.95% |
| 2016-12-31 | ₩48.60 Billion | +7.29% |
| 2015-12-31 | ₩45.30 Billion | +5.00% |
| 2014-12-31 | ₩43.14 Billion | +3.80% |
| 2013-12-31 | ₩41.57 Billion | -- |
Equity Component Analysis
This analysis shows how different components contribute to Seoulin Bioscience Co.Ltd's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have grown by 6916972564000.0% over the analyzed period, indicating profitable operations and earnings retention.
Current Equity Component Breakdown (December 2024)
| Component | Amount | Percentage |
|---|---|---|
| Retained Earnings | ₩69.17 Billion | 82.45% |
| Common Stock | ₩4.45 Billion | 5.30% |
| Other Components | ₩10.27 Billion | 12.24% |
| Total Equity | ₩83.89 Billion | 100.00% |
Seoulin Bioscience Co.Ltd Competitors by Market Cap
The table below lists competitors of Seoulin Bioscience Co.Ltd ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Hoffmann Green Cement Technologies
PA:ALHGR
|
$27.74 Million |
|
SRV YHTIOET OYJ
F:B7J1
|
$27.74 Million |
|
BF Investment Limited
NSE:BFINVEST
|
$27.74 Million |
|
Chumporn Palm Oil Industry Public Company Limited
BK:CPI
|
$27.76 Million |
|
K Way Information
TWO:5201
|
$27.70 Million |
|
HFB Financial Corp
PINK:HFBA
|
$27.69 Million |
|
JUNGDAWN Co. Ltd
KQ:208140
|
$27.69 Million |
|
Capita PLC
PINK:CTAGF
|
$27.67 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Seoulin Bioscience Co.Ltd's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2023 to 2024, total equity changed from 83,062,664,420 to 83,892,612,030, a change of 829,947,610 (1.0%).
- Net income of 2,913,907,220 contributed positively to equity growth.
- Dividend payments of 836,162,400 reduced retained earnings.
- Share repurchases of 1,092,264,120 reduced equity.
Equity Change Factors (2023 to 2024)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | ₩2.91 Billion | +3.47% |
| Dividends Paid | ₩836.16 Million | -1.0% |
| Share Repurchases | ₩1.09 Billion | -1.3% |
| Other Changes | ₩-155.53 Million | -0.19% |
| Total Change | ₩- | 1.00% |
Book Value vs Market Value Analysis
This analysis compares Seoulin Bioscience Co.Ltd's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 0.66x
- The company is trading below its book value, potentially indicating the market believes the assets are overvalued on the balance sheet or anticipates future losses.
- The price-to-book ratio has decreased from 1.09x to 0.66x over the analyzed period, indicating reduced market premium.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2016-12-31 | ₩6059.89 | ₩6600.00 | x |
| 2017-12-31 | ₩6244.98 | ₩6600.00 | x |
| 2018-12-31 | ₩6469.17 | ₩6600.00 | x |
| 2019-12-31 | ₩7270.04 | ₩6600.00 | x |
| 2020-12-31 | ₩7314.70 | ₩6600.00 | x |
| 2021-12-31 | ₩8927.77 | ₩6600.00 | x |
| 2022-12-31 | ₩10251.49 | ₩6600.00 | x |
| 2023-12-31 | ₩9703.72 | ₩6600.00 | x |
| 2024-12-31 | ₩9944.62 | ₩6600.00 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Seoulin Bioscience Co.Ltd utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): 3.47%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: 3.86%
- • Asset Turnover: 0.74x
- • Equity Multiplier: 1.21x
- Recent ROE (3.47%) is below the historical average (8.08%), suggesting potential challenges in capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2013 | 10.12% | 9.86% | 0.70x | 1.47x | ₩49.21 Million |
| 2014 | 6.25% | 7.08% | 0.62x | 1.42x | ₩-1.60 Billion |
| 2015 | 4.03% | 4.38% | 0.63x | 1.46x | ₩-2.71 Billion |
| 2016 | 8.38% | 9.07% | 0.68x | 1.37x | ₩-787.55 Million |
| 2017 | 4.00% | 4.84% | 0.60x | 1.38x | ₩-3.09 Billion |
| 2018 | 4.89% | 5.26% | 0.70x | 1.32x | ₩-2.75 Billion |
| 2019 | 14.88% | 16.33% | 0.67x | 1.35x | ₩2.91 Billion |
| 2020 | 8.17% | 7.52% | 0.83x | 1.31x | ₩-1.10 Billion |
| 2021 | 20.82% | 19.36% | 0.59x | 1.82x | ₩8.10 Billion |
| 2022 | 12.12% | 9.70% | 0.78x | 1.61x | ₩1.78 Billion |
| 2023 | -0.14% | -0.13% | 0.79x | 1.37x | ₩-8.42 Billion |
| 2024 | 3.47% | 3.86% | 0.74x | 1.21x | ₩-5.48 Billion |
Industry Comparison
This section compares Seoulin Bioscience Co.Ltd's net assets metrics with peer companies in the Biotechnology industry.
Industry Context
- Industry: Biotechnology
- Average net assets among peers: $227,267,185,369
- Average return on equity (ROE) among peers: -12.07%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Seoulin Bioscience Co.Ltd (038070) | ₩86.36 Billion | 10.12% | 0.31x | $27.72 Million |
| ORIENTBIO Inc. (002630) | $67.35 Billion | -2.60% | 1.21x | $28.10 Million |
| Green Cross (005250) | $282.15 Billion | 18.83% | 0.53x | $228.88 Million |
| Green Cross Holdings Preference Shares (005257) | $1.44 Trillion | 3.01% | 0.78x | $410.72 Million |
| Pharmicell (005690) | $9.90 Billion | -119.73% | 2.00x | $438.14 Million |
| GeneOne Life Science Inc (011000) | $39.74 Billion | 0.00% | 0.49x | $53.78 Million |
| HLB Co. Ltd (028300) | $77.24 Billion | -21.40% | 1.44x | $4.11 Billion |
| Daesung Microbiological Labs. Co. Ltd (036480) | $25.09 Billion | 18.13% | 0.29x | $14.92 Million |
| Hyundai Bioscience Co. Ltd (048410) | $39.30 Billion | 0.00% | 0.56x | $899.28 Million |
| iNtRON Biotechnology Inc (048530) | $64.96 Billion | -4.91% | 0.37x | $83.99 Million |